Highest-materiality recent filing
Jasper Therapeutics acquires Kira Pharmaceuticals; issues ~9.8M shares and raises $132M PIPE
Jasper issued ~5.2M common shares and ~4.6M convertible preferred shares to Kira shareholders; Kira holders own ~88.73% of pro forma common pre-PIPE.
Jasper Therapeutics completes all-stock acquisition of Kira Pharmaceuticals and $132M PIPE
Jasper acquires Kira in all-stock deal; pre-deal Jasper holders own ~6.68%, Kira holders ~49.86%, PIPE investors ~43.46% of combined company.
Jasper Therapeutics receives Nasdaq bid price deficiency notice; 180 days to cure
On June 3, 2026, Nasdaq notified Jasper that its common stock bid price closed below $1.00 for 30 consecutive business days.
Jasper Therapeutics initiates strategic review including potential sale or wind-down
Board of Directors initiates comprehensive review of strategic alternatives to maximize shareholder value.
Jasper posts Q4 net loss $9.1M; cash $28.7M; appoints new CEO; reports positive CSU/asthma data
Jeet Mahal named President and CEO to lead next phase of clinical growth.
67% (4/6) of new BEACON briquilimab patients achieved complete response at week 12; mean UAS7 drop of 31 points.
Effective Jan 5, 2026, Jeet Mahal becomes CEO and President; he also joins the Board as Class III director.
Jasper reports positive ETESIAN asthma data; BEACON investigation clears drug product
Single 180mg briquilimab reduced sputum eosinophils from 10.3% to 2.32% at 6 weeks post-allergen challenge.
Jasper Q3 net loss $18.7M; BEACON investigation finds no drug quality issues; cash $50.9M
Net loss of $18.7M ($1.13 per share); R&D expense $14.4M, G&A $4.8M.
Jasper Therapeutics prices $30M public offering, updates BEACON CSU investigation progress
Gross proceeds ~$30M from offering of 11.67M shares + warrants at $2.43/share; closing expected Sept 22.
Jasper Therapeutics Q2 net loss $26.7M; cuts workforce 50%, probes BEACON lot issue
Net loss of $26.7M ($1.74 per share); cash and equivalents $39.5M as of June 30, 2025.
Jasper Therapeutics cuts workforce ~50%, halts non-urticaria programs; CMO departs
Workforce reduction of ~50% and halting of all non-chronic urticaria programs.
8 of 9 (89%) patients in 240mg and 360mg single-dose cohorts achieved complete response (UAS7=0).
Jasper Therapeutics: 92% complete response in 180mg cohort of briquilimab SPOTLIGHT study in CIndU
11 of 12 participants (92%) achieved complete response; 12 of 12 (100%) achieved clinical response within 8-week analysis.
Jasper Therapeutics Q1 2025 net loss $21.2M; cash $48.8M; briquilimab programs on track
Net loss of $21.2M ($1.41 per share) for Q1 2025; R&D expenses $16.2M, G&A $5.6M.
Company entered Open Market Sale Agreement with Jefferies LLC to sell up to $100M of common stock.
Jasper Therapeutics reports FY2024 net loss of $71.3M; briquilimab data positive
Cash and equivalents $71.6M at Dec 31, 2024; net loss $71.3M ($4.89 diluted EPS) for FY2024.
Mean UAS7 change of -26.6 at 8 weeks in 240mg single-dose cohort (N=3); all patients achieved Complete Response (UAS7=0).
Jasper Therapeutics Q3 net loss $18.6M, reports positive CIndU data, discontinues LR-MDS
Net loss $18.6M ($1.24 diluted EPS); cash $92.5M at Sept 30, 2024.
Jasper reports 93% clinical response rate in SPOTLIGHT study of briquilimab in CIndU
14 of 15 patients (93%) achieved clinical response; 10 of 12 (83%) in 120mg cohort had complete response.
Net loss for FY2023: $64.5M ($6.18 diluted EPS); Q4 net loss $16.6M ($1.50 diluted EPS).
Jasper Therapeutics prices $50M underwritten offering of 3.9M shares at $12.95/share
Gross proceeds ~$50M from 3,900,000 shares of common stock at $12.95 per share.
Net loss of $17.5M ($0.16 per share); R&D expenses $14.8M; G&A expenses $4.5M.
Jasper appoints Thomas G. Wiggans as Chairperson; William Lis to retire in Dec 2023
Thomas G. Wiggans joins Board as Class II director and Chairperson effective Nov 1, 2023.
Notice from Nasdaq: common stock bid price below $1.00 for 30 consecutive business days.
FDA cleared IND for Phase 1b/2a repeat dose study of subcutaneous briquilimab in CSU patients.
All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recovery.
FDA provided guidance on the proposed program for briquilimab for chronic spontaneous urticaria (CSU).
Jasper Therapeutics Q1 net loss widens to $14.3M; de-prioritizes AML/MDS Phase 3
Net loss of $14.3M in Q1 2023 vs $2.2M in Q1 2022, driven by increased R&D and warrant liability changes.
Jasper Therapeutics FY2022 net loss $37.7M; expands briquilimab to chronic urticaria, raises $101.4M
FY2022 net loss $37.7M vs $30.6M in 2021; R&D $34.6M, G&A $16.6M.
Appointed Vishal Kapoor to board effective Feb 16, 2023; he is Partner at Avego Management and received option for 109,383 shares at $1.83.
Jasper Therapeutics reports positive briquilimab data: 3 SCD patients achieve 100% donor chimerism
First two sickle cell disease patients achieved 100% donor myeloid chimerism at Day 100; third at Day 30.
Jasper Therapeutics closes $103.5M public offering of 69M shares at $1.50/share
Closed underwritten offering of 69,000,000 shares at $1.50, including 9M option shares.
Jasper Therapeutics prices $90M public offering of 60M shares at $1.50 per share
Offering of 60M shares of common stock at $1.50/share; gross proceeds ~$90M before expenses.
Jasper Therapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq letter on Jan 18, 2023 confirming full compliance with Listing Rule 5550(a)(2).
On May 15, 2026 (the “Notice Date”), Christian Nolet informed the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) that he is resigning from the Board and the committees of the Board on which he serves, effective as of the Notice Date.
On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.
Effective immediately following Dr. French’s resignation, on June 18, 2024, the Board appointed Svetlana Lucas, Ph.D. as a Class III director of the Company.
Effective November 1, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Thomas G. Wiggans as a Class II director of the Company. Mr. Wiggans was also appointed to serve as Chairperson of the Board.
On September 21, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Herb Cross, age 51 , as its Chief Financial Officer and Corporate Secretary.
the Board approved the transition of Jeet Mahal, the Company’s Chief Financial Officer and Chief Operating Officer, to serve solely as the Company’s Chief Operating Officer.
Effective June 20, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Scott Brun, M.D., as a Class I director of the Company.
Effective February 16, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Vishal Kapoor as a Class I director of the Company.
Dr. Heller’s employment with the Company will terminate, effective May 17, 2022.
On March 18, 2022, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) approved the promotion of Jeet Mahal, age 50, the Company’s Chief Financial Officer and Chief Business Officer, to Chief Operating Officer and Chief Financial Officer, effective March 21, 2022.
Mr. Lis will continue serving as a Class III director of the Company and will commence serving as a non-employee Chairperson of the Company’s Board of Directors (the “Board”).
On March 7, 2022, in connection with the appointment of Ronald Martell as the President and Chief Executive Officer of Jasper Therapeutics, Inc. (the “Company”),
Max materiality 1.00 · Median 0.65 · Most common event other_material